Single Dose of Dengue Vaccine Shows Strong Immune Response
Author Information
Author(s): Anna P. Durbin, Stephen S. Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhavin Thumar, Joseph E. Blaney, Brian R. Murphy, Alexander C. Schmidt
Primary Institution: Johns Hopkins Bloomberg School of Public Health
Hypothesis
Can a single dose of the rDEN1Δ30 vaccine induce sufficient immunity against dengue fever?
Conclusion
The rDEN1Δ30 vaccine is safe and induces strong immunity, but a second dose does not enhance the immune response.
Supporting Evidence
- The first dose of the vaccine was well tolerated and induced seroconversion in 92% of vaccinees.
- Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose.
- The vaccine induced sterilizing humoral immunity in most vaccinees for at least six months.
Takeaway
The dengue vaccine rDEN1Δ30 works well with just one shot, but getting a second shot later doesn't help much.
Methodology
This was a randomized, double-blind, placebo-controlled trial with two cohorts receiving either the vaccine or placebo.
Potential Biases
The study was conducted at a single institution, which may limit generalizability.
Limitations
The study's findings may not apply to partially immune children, who are a target group for vaccination.
Participant Demographics
Participants were healthy adults aged 18 to 50, with a majority being Black.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website